Sanofi (SNY) EPS (Weighted Average and Diluted) Growth (1y) (2010 - 2025)
Sanofi (SNY) EPS (Weighted Average and Diluted) Growth (1y) (2010 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EPS (Weighted Avg. Diluted) Growth (1y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
- |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
169.93% |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
-52.86% |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
-45.83% |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
-185.57% |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
4.37% |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
54.81% |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
-9.62% |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
9.17% |
| 10 |
Sanofi |
63.47 Mn |
-6.87 Bn |
9.49 Bn |
- |
| Date | Value |
|---|
| Dec 31, 2025 |
-1,551.33% |
| Jun 30, 2025 |
4,002.66% |
| Dec 31, 2024 |
59.44% |
| Jun 30, 2024 |
-96.77% |
| Dec 31, 2023 |
-106.71% |
| Jun 30, 2023 |
27.93% |
| Dec 31, 2022 |
2,484.45% |
| Jun 30, 2022 |
-22.81% |
| Dec 31, 2021 |
-97.94% |
| Jun 30, 2021 |
476.62% |
| Dec 31, 2020 |
-99.99% |
| Jun 30, 2020 |
-135.28% |
| Dec 31, 2019 |
43,283,674.65% |
| Jun 30, 2019 |
-111.77% |
| Dec 31, 2018 |
9,654.15% |
| Jun 30, 2018 |
149.67% |
| Dec 31, 2017 |
-100.00% |
| Jun 30, 2017 |
-70.19% |
| Dec 31, 2016 |
474.97% |
| Jun 30, 2016 |
-25.84% |
